Results 51 to 60 of about 797,570 (234)

EL PLACEBO: LUCES Y SOMBRAS Placebo: Lights and shadows

Revista Habanera de Ciencias Médicas, 2008
Se realiza una revisión sobre el placebo definiéndose su concepto, así como del efecto placebo, sus reacciones en el organismo, utilidad en las investigaciones, sus posibles usos en la práctica médica y los peligros de su empleo.
José Díaz Novás
doaj  

Compreendendo o Efeito Placebo / Understanding the Placebo Effect

Revista Ciências em Saúde, 2015
RESUMO Placebo é definido em termos farmacológicos como uma substância inerte, sem propriedades farmacológicas intrínsecas. No entanto, essa definição é superficial, visto que o placebo pode gerar efeitos terapêuticos que dependem de diversos fatores ...
Elayne Vieira Dias, César Renato Sartori   +1 more
doaj   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial [PDF]

, 2020
Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Brighton, Paul (Paul J.), Brosens, Jan J., Da Costa, Maria José Minhoto Diniz, Ewington, Lauren J., Fishwick, Katherine, Fujihara, Risa, Kimani, Peter K., Lacey, Lauren, Lucas, Emma S., Muter, Joanne, Polanco, Angela, Quenby, Siobhan, Takeda, Satoru, Tewary, Shreeya   +13 more
core   +1 more source

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Heterogeneity of Rheumatoid Arthritis‐Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations with Disease Outcomes

Arthritis Care &Research, Accepted Article.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999‐2021. RA‐ILD patients were
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils [PDF]

, 2017
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
Brusselle, Guy, Germinaro, Matthew, Weiss, Sivan, Zangrilli, James   +3 more
core   +2 more sources

Cost‐effectiveness of low dose colchicine prophylaxis when starting allopurinol using the “start‐low go‐slow” approach for gout: evidence from a non‐inferiority randomised double‐blind placebo‐controlled trial.

Arthritis Care &Research, Accepted Article.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Re-evaluating the placebo response in recent canine dietary epilepsy trials

BMC Veterinary Research
The placebo response is a common phenomenon. Limited evidence is available about its magnitude in canine epilepsy trials, even though it can significantly influence the efficacy evaluation of new treatments.
Teresa Schmidt, Nina Meyerhoff, Sebastian Meller, Friederike Twele, Marios Charalambous, Benjamin A. Berk, Tsz H. Law, Rowena M. A. Packer, Brian Zanghi, Yuanlong Pan, Andrea Fischer, Holger A. Volk   +11 more
doaj   +1 more source

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study [PDF]

, 2015
Objectives The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients.
Bathon, Joan M., Beaulieu, Andre D., Carlson, Timothy H., Codding, Christine E., Delles, Christian, Giles, Jon T., Lee, Janet S., McInnes, Iain B., Salmon, Jane E., Sattar, Naveed, Thompson, Liz   +10 more
core   +1 more source